Session Title: Free Paper Session 9: AMD III
Session Date/Time: Friday 08/09/2017 | 08:00-09:30
Paper Time: 08:36
Venue: Room 117
First Author: : C.Türksever SWITZERLAND
Co Author(s): : C. Pruente K. Hatz
To study efficacy and safety of high frequency intravitreal ranibizumab in nAMD.
Prospective investigator initiated trial in Vista Klinik, Switzerland.
This clinical trial including 24 treatment naive patients with nAMD. Therapy was carried out at baseline, afterwards up to 2-weekly according to predefined retreatment criteria. The follow-up was weekly (0-6 month) and two-weekly (6-12 month) including SD-OCT. Predicting factors as well as structural and functional changes were evaluated. One patient was excluded from efficacy analysis (drop out).
Mean number of injections was 7.9±5.1. Half of patients (52%) required retreatment earlier than 4 weeks after baseline injection. BCVA (ETDRS letters) was improved from 67.8±9.5 to 70.3±12.2 (p=0.048) already at week 2. Central retinal thickness (CRT), intraretinal (IRF)- and subretinal fluid (SRF) were already significantly improved at week 1 (p=0.000; p=0.014; p=0.003), respectively. Baseline integrity of IS/OS line and ELM, respectively, was correlated with better baseline BCVA (p=0.02; p=0.006). Baseline integrity of ELM indicated better BCVA ( p=0.027) at month 12. A reduction of hyperreflective foci (HRF) at week 2 was associated with lower CRT (p=0.024) at month 12. Improvement in SRF at week 2 predicted BCVA improvement (p=0.041) at month 12. Greater range of fluctuation of CRT during 12 months led to lower BCVA (p=0.027) at month 12. No severe adverse events occured.
High-frequency ranibizumab treatment in nAMD is safe and efficient. More than half of patients need the first retreatment earlier than 4 weeks. Structural improvement after ranibizumab starts at 1 week.